Literature DB >> 17533013

Treatment of polycystic liver disease: one size does not fit all.

Vicente E Torres.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17533013     DOI： 10.1053/j.ajkd.2007.04.009

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  12 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

2.  High-resolution melt as a screening method in autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Grazia Maria Virzì; Alice Bruson; Valentina Corradi; Fiorella Gastaldon; Massimo de Cal; Marta Donà; Dinna N Cruz; Maurizio Clementi; Claudio Ronco
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

Review 3.  Molecular pathways and therapies in autosomal-dominant polycystic kidney disease.

Authors:  Takamitsu Saigusa; P Darwin Bell
Journal:  Physiology (Bethesda)       Date:  2015-05

Review 4.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

5.  ERCP for the treatment of bile leak after partial hepatectomy and fenestration for symptomatic polycystic liver disease.

Authors:  Nayantara Coelho-Prabhu; David M Nagorney; Todd H Baron
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

Review 6.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

7.  Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

Authors:  Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan
Journal:  Surgery       Date:  2020-05-08       Impact factor: 3.982

8.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

9.  Acute abdomen and ascites as presenting features of autosomal dominant polycystic kidney disease.

Authors:  Sanjay Chaudhary; Qi Qian
Journal:  World J Hepatol       Date:  2012-12-27

10.  Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients.

Authors:  Hayne Cho Park; Chi Weon Kim; Han Ro; Ju-Young Moon; Kook-Hwan Oh; Yonsu Kim; Jung Sang Lee; Yong Hu Yin; Hwan Jun Jae; Jin Wook Chung; Curie Ahn; Young-Hwan Hwang
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.